Britain and America have secured a key commercial pact that will guarantee zero import taxes on British pharmaceutical exports being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the NHS. This commitment guarantees that import taxes on these key exports will be held at nothing for a duration of three years.
This agreement follows earlier statements to hike import taxes on patented drug imports, with figures floated up to double the cost.
"This arrangement with the Britain bolsters the global environment for new treatments and establishes long-overdue equity to American-British pharmaceutical trade," a statement said.
Commercial Significance
Pharmaceuticals are one of the Britain's largest exports to the US, which is by far the primary destination for leading UK drugmakers.
Trade data show that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that span.
"This deal secures work, stimulates investment and paves the way for the UK to become a worldwide center for life sciences," a minister remarked.
Key UK Commitments
The pact includes several key changes from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at 15%. Previously, rebates topped twenty percent.
Industry Background
This agreement comes amid a protracted dispute between the drug companies and the UK government over drug pricing and regulatory access.
These tensions were heightened by claims that American consumers were charged several times more for the same drugs than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been halted or abandoned, while major funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
